Is Kratom an Opioid? What the Pharmacology and the Law Actually Say

Kratom is not an opiate, but its main compounds act on opioid receptors. Here is how the science, federal law and state law each answer the question.

Short answer: it depends on which kind of "opioid" you mean. Pharmacologically, kratom's two best-known alkaloids, mitragynine and 7-hydroxymitragynine (7-OH), activate mu-opioid receptors, the same targets as morphine. That's why the FDA and HHS describe kratom compounds, and especially 7-OH, as having opioid properties. Legally, plain kratom leaf is not on the federal list of controlled substances, but some kratom-derived compounds are now being scheduled, and several states already treat kratom's alkaloids as controlled.

So "kratom is just a plant, not an opioid" and "kratom is an opioid like any other" are both too simple. Here's how each part of the answer breaks down, with sources.

Opioid vs opiate: the word problem

An opiate is a drug derived from the opium poppy, such as morphine or codeine. Kratom (Mitragyna speciosa) is a tree in the coffee family, not a poppy, so it is not an opiate. Opioid is the broader term for any substance that acts on the body's opioid receptors, whatever its source. Synthetic drugs like fentanyl are opioids without being opiates.

When a vendor says "kratom isn't an opiate," that's accurate and beside the point. The useful question is what kratom compounds do at opioid receptors, and what that means for risk.

The pharmacology: what the research agencies say

Mitragynine and 7-OH both hit mu-opioid receptors

NIDA's kratom page (updated March 11, 2026) says both mitragynine and 7-OH activate mu-opioid receptors, but that the resulting effects "only partially compare" to drugs like heroin or oxycodone. It also notes that the way kratom compounds activate those receptors may reduce addiction potential relative to opioids. That last point is still being studied, not settled.

The FDA's position is firmer. Its kratom page says kratom compounds may produce classic opioid-related effects, including physical dependence and withdrawal, and that 7-OH "demonstrates substantially greater mu-opioid receptor potency" than both mitragynine and morphine. The FDA also notes that 7-OH makes up less than 2% of the alkaloids in natural leaf.

For a deeper look at the alkaloids themselves, see our guide to mitragynine and kratom alkaloids.

Respiratory depression and naloxone

Slowed breathing is what makes strong opioids deadly. NIDA says that in laboratory models, 7-OH can cause respiratory depression that is reversed by naloxone, the opioid-overdose reversal drug. That's a lab finding, not proof of how a given product behaves in a person. But it's one reason regulators treat concentrated 7-OH very differently from leaf.

Dependence

Both agencies describe withdrawal after regular use. NIDA characterizes it as mild to moderate in the studies it reviewed. NIDA also notes the DSM-5 has no kratom-specific diagnosis. Our dependence and withdrawal guide covers what that means for buyers.

Plain leaf vs 7-OH products

Most of the confusion in 2025 and 2026 comes from lumping two different product types together:

Our 7-OH vs natural leaf comparison goes through how to tell the categories apart on a label.

Federal law, as of October 2026

• Kratom leaf and mitragynine: not federally scheduled. NIDA notes that the DEA lists kratom as a "drug of concern." The DEA's October 2026 notice repeats that the agency still views kratom and its two major alkaloids as drugs of concern.
• FDA: no approved kratom drug, and kratom isn't lawfully marketed as a drug, dietary supplement or food additive, according to the agency. On July 29, 2025 the FDA recommended scheduling certain 7-OH products.
• DEA, July 2026: on July 1, 2026 the DEA announced notices of intent to temporarily schedule 7-OH above a threshold, plus mitragynine pseudoindoxyl, MGM-15 and MGM-16. In that announcement, the HHS Secretary called all four "dangerous opioids."
• DEA, October 2026: a revised notice of intent (Federal Register document 2026-20943, filed for publication October 14, 2026) would cover 7-OH and MP above a threshold. That means more than 1 mg per gram for solids or 1 mg per milliliter for liquids, or a ratio of mitragynine to those compounds below 100. It withdraws the July 7-OH notice. A temporary order cannot issue until 30 days after publication. The notice states plainly that the DEA has not found below-threshold levels to be safe.

Scheduling details are still moving. Our DEA 7-OH scheduling explainer tracks the steps, and the Federal Register is the final word. For MGM-15 and MGM-16, check the DEA's own site for current status.

State law: where kratom is already treated like a controlled opioid

Several states made this call years before the federal government. A June 2026 summary from the National Conference of State Legislatures (NCSL) lists Alabama, Arkansas, Indiana, Kansas, Louisiana, Vermont and Wisconsin as states that schedule kratom or its components in Schedule I. Kansas was added in April 2026. Tennessee enacted a statewide ban in 2026.

Arkansas makes the opioid framing explicit. Its controlled-substances list puts mitragynine and 7-hydroxymitragynine under the Schedule I heading "Opium derivatives." Kentucky, which otherwise regulates kratom sales, added 7-OH concentrated above 400 parts per million to Schedule I effective March 12, 2026.

Laws change, so check before buying. Our state-by-state legality guide is the place to start, and city and county rules can be stricter than state law.

Myths worth retiring

• "It's natural, so it's not an opioid." Origin doesn't decide receptor activity. The FDA and NIDA both describe mu-opioid receptor activation.
• "It's in the coffee family, so it's like coffee." Botanical family says nothing about effects or risk. We don't make effect claims, and neither has any regulator.
• "7-OH is just stronger kratom." Regulators treat concentrated and semi-synthetic 7-OH as a separate problem. The FDA put its potency above morphine at the receptor.
• "If it's sold in a store, it's legal and tested." The FDA says kratom isn't lawfully marketed as a supplement at all. A shelf placement is not a safety review.
• "It's an opioid, so it's as dangerous as fentanyl." NIDA says fatal overdose from kratom alone is extremely rare, and it links severe adverse effects to polysubstance use. "Not as dangerous as fentanyl" is still a long way from safe.

What this means before you buy

1. Treat kratom as a substance with opioid-receptor activity. That's why mixing it with opioids, benzodiazepines, alcohol or other sedatives is the risk regulators keep highlighting.
2. Avoid products sold on potency, and anything marketed as 7-OH, "enhanced," or with no lot-matched lab report. Our guide to spotting synthetic 7-OH shows what to look for.
3. Talk to a doctor or pharmacist first, especially if you take any opioid, a medication for opioid use disorder, or a sedative.

The FDA has not approved kratom for any use, there is no established safe dose, and anyone considering it should talk to a clinician first.

Sources

• NIDA, "Kratom" (updated March 11, 2026): nida.nih.gov
• FDA, "FDA and Kratom" (updated December 2, 2025): fda.gov
• HHS, FDA 7-OH scheduling recommendation (July 29, 2025): hhs.gov
• DEA bulletin, notices of intent to temporarily schedule 7-OH and related substances (July 1, 2026): DEA via GovDelivery
• DEA notice of intent, FR Doc. 2026-20943 (public inspection, October 2026): federalregister.gov
• NCSL, "Lawmakers Weigh Guardrails, Bans on Kratom and 7-OH" (June 30, 2026): ncsl.org
• Arkansas List of Controlled Substances, 007.07.18 Ark. Code R. 002: law.cornell.edu
• Kentucky 902 KAR 55:015: legislature.ky.gov